Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
Completed · Phase 1/Phase 2
Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm
In brief
RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who have recurrent or refractory multiple myeloma.
Key facts
- Study ID
- NCT00060203
- Run by
- Case Comprehensive Cancer Center
- People needed
- 3
- Starts
- 2002-12-01
- Expected to finish
- 2004-04-01
- Last updated by the study team
- 2014-01-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Ireland Cancer Center — Cleveland, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.